Search

Displaying results 3761 - 3770 of 10000 in total
  1. Pathway

    Acylcarnitine (9E,11E,15Z)-9-hydroxyoctadeca-9,11,15-trienoylcarnitine

    smpdb.ca/view/SMP0124345
    Metabolic

    (9E,11E,15Z)-9-hydroxyoctadeca-9,11,15-trienoylcarnitine is an acylcarnitine. … In forming an acylcarnitine derivative, (9E,11E,15Z)-9-hydroxyoctadeca-9,11,15-trienoyl-CoA reacts with L-carnitine to form (9E,11E,15Z)-9-hydroxyoctadeca-9,11,15-trienoylcarnitine.

    Drugs: Biotin · Adenosine phosphate · ATP · Levocarnitine · Magnesium cation · Pyrophosphoric acid +1 more
  2. Pathway

    Acylcarnitine (9Z,12Z,15Z)-17-hydroxyoctadeca-9,12,15-trienoylcarnitine

    smpdb.ca/view/SMP0124346
    Metabolic

    (9Z,12Z,15Z)-17-hydroxyoctadeca-9,12,15-trienoylcarnitine is an acylcarnitine. … In forming an acylcarnitine derivative, (9Z,12Z,15Z)-17-hydroxyoctadeca-9,12,15-trienoyl-CoA reacts with L-carnitine to form (9Z,12Z,15Z)-17-hydroxyoctadeca-9,12,15-trienoylcarnitine.

    Drugs: Biotin · Adenosine phosphate · ATP · Levocarnitine · Magnesium cation · Pyrophosphoric acid +1 more
  3. Drug

    PHB-050

    go.drugbank.com/drugs/DB32061
    Experimental

    PHB-050 is a novel, next-generation anti-IgE antibody designed to block IgE from binding to mast cells, while also rapidly reducing circulating IgE and inhibiting its production.

  4. Drug

    Cinchocaine

    go.drugbank.com/drugs/DB00527
    ApprovedVet approved

    A local anesthetic of the amide type now generally used for surface anesthesia.

    Mixtures: ULTRAPROCT %0,09+%0,09+%0,5 MERHEM, 10 G, Dibucaine HCl 0.5% / Lidocaine 15% / Phenylephrine HCl 1% / Prilocaine 5%
  5. Drug

    Sulfadimethoxine

    go.drugbank.com/drugs/DB06150
    ApprovedVet approvedWithdrawn

    It is widely available in Russia as an over-the-counter drug manufactured by a number of Russian pharmaceutical companies. … Sulfadimethoxine is a sulfonamide antibiotic. Sulfadimethoxine is used to treat many infections, including treatment of respiratory, urinary tract, enteric, and soft tissue infections.

    Mixtures: TP-SULTRIXIN 40/200MG/ML SOLUTION, TP-SULTRIME 80/400MG/G POWDERCategories: Cytochrome P-450 CYP2C9 Inhibitors, Cytochrome P-450 Enzyme Inhibitors
  6. Drug

    Benzophenone

    go.drugbank.com/drugs/DB01878
    Approved

    Benzophenone is the organic compound. Substituted benzophenones such as oxybenzone and dioxybenzone are used in sunscreen.

    Mixtures: Daily Moisturizing SPF 15, nanocare Moisturizing Sunscreen SPF 50
  7. Drug

    Azatadine

    go.drugbank.com/drugs/DB00719
    ApprovedWithdrawn

    Antihistamines such as azatadine appear to compete with histamine for histamine H1- receptor sites on effector cells. The antihistamines antagonize those pharmacological effects of histamine which are mediated through activation of H1- r...

    Mixtures: AFRINEX HAProducts: Optimine Tab 1mg
  8. Drug

    Pemigatinib

    go.drugbank.com/drugs/DB15102
    ApprovedInvestigational

    This malignancy accounts for 15% to 20% of primary hepatobiliary malignancies, which account for 13% of overall cancer-related global mortality. … Pemigatinib is a small molecule kinase inhibitor with antitumour activity.

    Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP3A Substrates
  9. Drug

    Tividenofusp alfa

    go.drugbank.com/drugs/DB17628
    ApprovedInvestigational

    Hunter syndrome is a rare, X-linked lysosomal storage disorder caused by a deficiency in the enzyme iduronate-2-sulfatase (IDS), which leads to the toxic accumulation of glycosaminoglycans (GAGs) throughout … Tividenofusp alfa is a recombinant human IDS fused to a monoclonal antibody that targets the human insulin receptor (HIR), utilizing receptor-mediated transcytosis to gain access to the central nervous

    Synonyms: 676>S, L 678>A, Y, - L-iduronate sulfate sulfatase, EC:3.1.6.13) pro-protein (1-525), fused via the peptide linker 526 GGGGS 530 to a human immunoglobulin G1 C-terminal Fc fragment (531-757) variant (L 544>A, L 545>A, T
  10. Drug

    Leronlimab

    go.drugbank.com/drugs/DB05941
    Investigational

    Leronlimab, or PRO-140, is a human monoclonal antibody developed by CytoDyn.[L12684] It was first described in the literature in 2001.